Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2016

View Archived Issues

Allergan completes acquisition of Chase Pharmaceuticals

Viral Gene announces phase II funding for novel vaccine to prevent colon cancer metastases

Juno Therapeutics places clinical hold on phase II ROCKET trial of JCAR-015

Proteros and Merck Sharp & Dohme sign second oncology collaboration on epigenetic target

SM-04755 demonstrates promise in models of psoriasis, chronic tendinopathy and scleroderma

LPA receptor 1 as a target for diabetic nephropathy

Pfizer patents myeloperoxidase irreversible inhibitors

Genentech and Roche disclose retinoid RORgamma receptor ligands

Pfizer describes JAK inhibitors

Rayaldee set for U.S. launch

Sun Pharma signs definitive agreement to acquire JSC Biosintez

Sanofi Pasteur MSD vaccines joint venture to end next month

PRX-OTC from PhaseRx receives FDA orphan drug designation

European Commission grants conditional marketing authorization for Ninlaro

Institute of Human Virology announces grants and new international center to tackle HIV/AIDS

Navidea signs Lymphoseek asset purchase agreement with Cardinal Health

FDA grants orphan drug designation to ABTL-0812 for the treatment of pancreatic cancer

NeuroSearch outlines plan for remaining assets after Danish Supreme Court decision

Filgotinib begins phase III trial in Crohn's disease

C3c may be useful to monitor psoriatic arthritis

Arsanis initiates phase II trial of ASN-100 to prevent S. aureus pneumonia

RGC upregulation may have a pathogenic role in lupus nephritis

Xencor initiates phase I study of XmAb-13676 for CD20-expressing hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...